---
schema_version: "secwatch.filing_event.v1"
accession: "0001610618-24-000121"
form_type: "8-K"
ticker: null
cik: "0001610618"
company_name: "Cidara Therapeutics, Inc."
filed_at: "2024-09-12T23:59:59+00:00"
generated_at: "2026-05-31T05:14:21.612858+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cidara cuts 30% of workforce, focuses on CD388 influenza program; Phase 2b planned Q3 2024

## Summary
- Reduction of 20 employees (~30% of workforce); charges ~$1.2M for severance and benefits in Q4 2024.
- Workforce reduction expected to be substantially completed by November 1, 2024.
- Company will focus entirely on CD388 influenza candidate; no other clinical trials currently planned.
- Phase 2b clinical trial of CD388 for influenza prevention expected to initiate in Q3 2024.

## SEC filing metadata
- accession: 0001610618-24-000121
- form_type: 8-K
- cik: 0001610618
- company_name: Cidara Therapeutics, Inc.
- filed_at: 2024-09-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.05, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610618/000161061824000121/0001610618-24-000121-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610618/000161061824000121/cdtx-20240909.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001610618-24-000121
- JSON: https://secwatch.observer/filing/0001610618-24-000121.json
- Plain text: https://secwatch.observer/filing/0001610618-24-000121.txt

## Key facts
- Restructurings & Charges
  Cidara Therapeutics, Inc. announced a restructuring with charges of approximately $1.2 million (20 employees).
  - Type: restructuring
  - Charge: approximately $1.2 million
  - Headcount: 20 employees
  source text: its influenza product candidate. The Reduction is expected to be substantially completed by November 1, 2024. The Company estimates that it will incur charges of approximately $1.2 million for severance payments and employee benefits, primarily in the fourth quarter of 2024. Substantially all of the estimated charges are expected to result in future cash
  evidence_url: https://www.sec.gov/Archives/edgar/data/1610618/000161061824000121/0001610618-24-000121-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.